Atara Biotherapeutics, Inc.
NMS: ATRALive Quote
📈 ZcoreAI Score
Our AI model analyzes Atara Biotherapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get ATRA Z-Score →About Atara Biotherapeutics, Inc.
Healthcare
Biotechnology
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
📊 Fundamental Analysis
Atara Biotherapeutics, Inc. demonstrates exceptional profitability, with a profit margin of 27.1%.
The company recently reported -95.1% revenue growth, which is negative, indicating a recent decline in revenue.
At a current price of $4.65, ATRA currently trades near the bottom of its 52-week range (5%), indicating potential value or weakness (Range: $3.92 - $19.14).
💰 Valuation Insight
ATRA trades at a 92.8% discount (PE: 1.81), which may represent a value opportunity given the sector average of 25.00. Analysts anticipate some earnings pressure, with a higher forward PE.
🏥 Financial Health
✅
Profit Margin
Excellent
🔴
Revenue Growth
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$38.03M
Trailing P/E
1.81
Forward P/E
5.74
Beta (5Y)
-0.33
52W High
$19.14
52W Low
$3.92
Avg Volume
313K
Day High
Day Low